Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
World J Urol ; 41(6): 1563-1571, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37099197

ABSTRACT

PURPOSE: Few data are available regarding the nephrotoxicity of immune checkpoint inhibitor (ICI) combination therapy in advanced renal cell carcinoma (RCC). This study aimed to investigate the nephrotoxicity of ICI-based combination therapy versus standard of care sunitinib in patients with advanced RCC. METHODS: We searched Embase/PubMed/Cochrane Library for relevant randomized controlled trials (RCTs). Treatment-related nephrotoxicities including increase of creatinine and proteinuria were analyzed by Review Manager 5.4 software. RESULTS: Seven RCTs involving 5239 patients were included. The analysis showed that ICI combination therapy had similar risks of any grade (RR = 1.03, 95% CI: 0.77-1.37, P = 0.87) and grade 3-5 (RR = 1.48, 95% CI: 0.19-11.66, P = 0.71) increased creatinine compared with sunitinib monotherapy. However, ICI combination therapy was associated with significantly higher risks of any grade (RR = 2.33, 95% CI: 1.54-3.51, P < 0.0001) and grade 3-5 proteinuria (RR = 2.25, 95% CI: 1.21-4.17, P = 0.01). CONCLUSIONS: This meta-analysis suggests that ICI combination therapy shows more nephrotoxicity of proteinuria than sunitinib in advanced RCC, which deserves a high attention in the clinic.


Subject(s)
Carcinoma, Renal Cell , Kidney Neoplasms , Humans , Carcinoma, Renal Cell/drug therapy , Sunitinib/adverse effects , Immune Checkpoint Inhibitors/adverse effects , Creatinine , Kidney Neoplasms/pathology
2.
Drug Des Devel Ther ; 15: 2229-2242, 2021.
Article in English | MEDLINE | ID: mdl-34079224

ABSTRACT

OBJECTIVE: Total glucosides of paeony (TGP) has been proven to affect anti-inflammatory, immunomodulatory and hypoxia tolerance. This study investigates the effect of TGP on autophagy in acute kidney injury (AKI) induced by ischemia-reperfusion (I/R). METHODS: Rat model of AKI induced by I/R was established. Rats were administered with TGP at different doses by oral gavage. The contents of BUN, creatinine, NGAL, Kim-1 and IL-18 were detected. The levels of inflammatory factors (TNF-α, IL-1ß and IL-6) and autophagy were measured. The expressions of lncRNA TUG1, miR-29a and PTEN were detected and their binding relationships were verified. I/R rat model with overexpressed TUG1 was established to explore the effect of TGP on kidney injury and autophagy. The hypoxia/reoxygenation (HR) model of HK-2 cells and the HR model of HK-2 cells overexpressing TUG1 and low-expressing PTEN were established. RESULTS: TGP decreased the contents of BUN, creatinine, NGAL, Kim-1 and IL-18, and reduced the levels of inflammatory factors. LncRNA TUG1 and PTEN were downregulated, and miR-29a was upregulated in kidney tissues. The binding relationships between lncRNA TUG1 and miR-29a, and miR-29a and PTEN were confirmed. TGP suppressed PTEN expression via the lncRNA TUG1/miR-29a axis. Overexpressing lncRNA TUG1 attenuated the protective effect of TGP on AKI and autophagy in HK-2 cells. TGP improved cell viability and inhibited the autophagy in HR model of HK-2 cells via lncRNA TUG1/miR-29a/PTEN axis. CONCLUSION: TGP inhibited autophagy and improved AKI induced by I/R via the lncRNA TUG1/miR-29a/PTEN axis.


Subject(s)
Acute Kidney Injury/drug therapy , Glucosides/pharmacology , MicroRNAs/antagonists & inhibitors , PTEN Phosphohydrolase/antagonists & inhibitors , Paeonia/chemistry , RNA, Long Noncoding/antagonists & inhibitors , Acute Kidney Injury/pathology , Administration, Oral , Animals , Autophagy/drug effects , Cells, Cultured , Disease Models, Animal , Glucosides/administration & dosage , Glucosides/chemistry , Male , MicroRNAs/metabolism , PTEN Phosphohydrolase/metabolism , RNA, Long Noncoding/metabolism , Rats , Rats, Sprague-Dawley , Reperfusion Injury
3.
FASEB J ; 33(8): 9279-9290, 2019 08.
Article in English | MEDLINE | ID: mdl-31162940

ABSTRACT

Diabetes nephropathy (DN) is characterized by abnormal interactions between kidney-infiltrating macrophages and glomerular mesangial cells. Recently, a novel cell-cell communication mediated by exosomes has gained attention. Exosomes are membrane-bound vesicles that contain a variety of molecules such as proteins, lipids, DNA, mRNA, and microRNAs. Exosomes play an important role in the pathogenesis of DN. In this study, we show that high glucose (HG) led to increased excretion of exosomes from macrophages. Mesangial cells took up exosomes in vitro, which resulted in the activation and proliferation of mesangial cells and the secretion of extracellular matrix and inflammatory cytokines. In addition, C57BL/6 mice injected with exosomes from HG-treated macrophages showed morphologic and functional changes. We then showed that exosomes from HG-treated TGF-ß1 knockdown macrophages induced less extracellular matrix and fewer inflammatory factors in mesangial cells compared with vector control. Our findings suggest that TGF-ß1 mRNA in exosomes serves a role between macrophages and mesangial cells by activating the TGF-ß1/ mothers against decapentaplegic homolog 3 pathway.-Zhu, Q.-J., Zhu, M., Xu, M.-X., Meng, X.-M., Wu, Y.-G. Exosomes from high glucose-treated macrophages activate glomerular mesangial cells via TGF-ß1/Smad3 pathway in vivo and in vitro.


Subject(s)
Exosomes/drug effects , Exosomes/metabolism , Glucose/pharmacology , Macrophages/drug effects , Macrophages/metabolism , Smad3 Protein/metabolism , Transforming Growth Factor beta1/metabolism , Animals , Cell Line , Cells, Cultured , Enzyme-Linked Immunosorbent Assay , Immunohistochemistry , Male , Mesangial Cells/drug effects , Mesangial Cells/metabolism , Mice , Mice, Inbred C57BL , Microscopy, Confocal , Microscopy, Electron, Transmission , Signal Transduction/drug effects
4.
Ren Fail ; 41(1): 244-256, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31014155

ABSTRACT

PURPOSE: To date, the prevalence and prognostic role of coronary artery calcification (CAC) in patients with chronic kidney disease (CKD) have been investigated in several studies, but have yielded conflicting results. The aim of this meta-analysis is to derive a more precise estimation of CAC prevalence in CKD patients and its association with cardiovascular events and mortality. METHODS: The relevant literature was identified and evaluated from inception until July 2018 through multiple search strategies on PubMed, Embase, and Web of Science. Cross-sectional or cohort (baseline data) studies reporting CAC prevalence were included. Data extracted from eligible studies were used to calculate effect estimates (ESs) and 95% confidence intervals (95%CI). We searched databases for observational studies that explored baseline CAC and subsequent cardiovascular or all-cause mortality risk in CKD patients. RESULTS: The meta-analysis included 47 studies; 38 of these were included in the final analysis of CAC prevalence. The pooled prevalence of CAC in random effect model was 60% (95%CI 53-68%). CAC was positively associated with an increased risk of all-cause mortality (hazard ratio [HR] 3.44; 95%CI 2.40-4.94), cardiovascular mortality (HR 3.87; 95%CI 2.06-7.26), and cardiovascular events (HR 2.09; 95%CI 1.19-3.67), when comparing individuals in the top CAC score group to those in the bottom CAC score group. CONCLUSIONS: The pooled prevalence of CAC is highly prevalent. CAC is independently associated with all-cause and cardiovascular mortality risk as well as cardiovascular events among CKD patients. In view of the high heterogeneity, larger clinical trials are still needed.


Subject(s)
Coronary Artery Disease/epidemiology , Renal Insufficiency, Chronic/mortality , Vascular Calcification/epidemiology , Coronary Artery Disease/pathology , Coronary Vessels/pathology , Humans , Prevalence , Prognosis , Renal Insufficiency, Chronic/complications , Risk Assessment , Risk Factors , Vascular Calcification/pathology
5.
Drug Des Devel Ther ; 11: 3221-3233, 2017.
Article in English | MEDLINE | ID: mdl-29184392

ABSTRACT

Toll-like receptors (TLRs) may be involved in diabetic nephropathy (DN). Paeoniflorin (PF) is an effective Chinese traditional medicine with anti-inflammatory and immunoregulatory effects that may inhibit the TLR2 signaling pathway. In this study, we investigated the effects of PF on the kidneys of mice with streptozotocin-induced type 1 diabetes mellitus using TLR2 knockout mice (TLR2-/-) and wild-type littermates (C57BL/6J-WT). After 12 weeks of intraperitoneal injection of PF at doses of 25, 50, and 100 mg/kg once a day, diabetic mice had significantly reduced albuminuria and attenuated renal histopathology. These changes were associated with substantially alleviated macrophage infiltration and decreased expression of TLR2 signaling pathway biomarkers. These data support a role of TLR2 in promoting inflammation and indicate that the effect of PF is associated with the inhibition of the TLR2 pathway in the kidneys of diabetic mice. PF thus shows therapeutic potential for the prevention and treatment of DN.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Diabetic Nephropathies/drug therapy , Glucosides/pharmacology , Monoterpenes/pharmacology , Signal Transduction/drug effects , Toll-Like Receptor 2/antagonists & inhibitors , Animals , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Diabetic Nephropathies/chemically induced , Diabetic Nephropathies/pathology , Dose-Response Relationship, Drug , Glucosides/chemistry , Mice , Mice, Inbred C57BL , Mice, Knockout , Molecular Conformation , Monoterpenes/chemistry , Streptozocin , Structure-Activity Relationship , Toll-Like Receptor 2/deficiency , Toll-Like Receptor 2/metabolism
6.
J Pharmacol Sci ; 125(1): 59-67, 2014.
Article in English | MEDLINE | ID: mdl-24739281

ABSTRACT

Accumulating evidence suggested that macrophages induce tubulointerstitial injury. Total glucosides of paeony (TGP), extracted from Paeonia lactiflora, has presented anti-inflammatory activities in diabetic kidney disease. This research will investigate the protective effect of TGP on renal tubulointerstitium and its mechanism in streptozotocin-induced diabetic rats. TGP was administered orally at a dose of 50, 100, and 200 mg·kg(-1)·d(-1) for 8 weeks. Tubulointerstitial injury was quantified, followed by immunohistochemistry analysis of renal α-smooth muscle actin (α-SMA), E-cadherin (E-cad) expression, nuclear factor kappa B (NF-κB)-p-p-65(+), Toll-like receptor (TLR)2(+), and ED-1(+) cell infiltration in renal tubulointerstitium. Renal TLR2(+) macrophages were detected by double immunohistochemical staining. Western blotting was used to detect the TLR2 expression. Histologically, there was marked accumulation of TLR2(+), NF-κB-p-p-65(+), ED-1(+) cells, and ED-1(+)TLR2(+) cells (macrophages) in the diabetic kidney and TGP treatment could alleviate it. Accompanying with that, the tubulointerstitial injury was ameliorated, α-SMA expression was lower, and E-cad expression was higher compared with the diabetic rats. Western blot analysis showed that the expression of TLR2 protein was significantly increased in the kidney of the diabetic rats, whereas TGP treatment reduced it. Our study showed that TGP could prevent renal tubulointerstitium injury in diabetic rats through a mechanism that may be at least partly correlated with suppression of increased macrophage infiltration and the expression of TLR2.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Diabetes Mellitus, Experimental/complications , Glucosides/pharmacology , Nephritis, Interstitial/drug therapy , Nephritis, Interstitial/prevention & control , Paeonia/chemistry , Toll-Like Receptor 2/metabolism , Actins/analysis , Administration, Oral , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/isolation & purification , Biomarkers/analysis , Cadherins/analysis , Disease Models, Animal , Glucosides/administration & dosage , Glucosides/chemistry , Glucosides/isolation & purification , Immunohistochemistry , Kidney/immunology , Kidney/pathology , Macrophage Activation/drug effects , Male , Molecular Conformation , NF-kappa B/analysis , Nephritis, Interstitial/diagnosis , Nephritis, Interstitial/etiology , Phytotherapy , Rats , Rats, Wistar , Streptozocin
7.
Phytomedicine ; 21(6): 815-23, 2014 May 15.
Article in English | MEDLINE | ID: mdl-24462407

ABSTRACT

TLRs are a family of receptors that play a critical role in the pathogenesis of diabetic nephropathy. TGP have been shown to have anti-inflammatory and immuno-regulatory activities. However, the relation between TGP and TLRs on diabetic nephropathy remains unknown. In this study, we examined effects of TGP on immune regulatory TLR2 and 4 in the kidney from streptozotocin-induced diabetic rats. TGP decreased the levels of 24h urinary albumin excretion rate significantly in diabetic rats. Western blot analysis showed that TGP significantly inhibited the expression of TLR2 and 4, MyD88, p-IRAK1, NF-κB p65, p-IRF3, TNF-α and IL-1ß. Quantitative real-time PCR analysis showed that the significantly increased levels of TLR2 and 4, and MyD88mRNA in the kidneys of diabetic rats were significantly suppressed by TGP treatment. Macrophages infiltration were also markedly increased in the kidneys of the diabetic rats, but were significantly inhibited by TGP in a dose-dependent manner. These results suggest that TGP has protective effects on several pharmacological targets in the progress of diabetic nephropathy by selectively blocking TLRs activation in vivo.


Subject(s)
Diabetic Nephropathies/drug therapy , Glucosides/therapeutic use , Kidney/drug effects , Paeonia/chemistry , Phytotherapy , Toll-Like Receptor 2/metabolism , Toll-Like Receptor 4/metabolism , Albumins/metabolism , Animals , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Experimental/drug therapy , Diabetic Nephropathies/metabolism , Glucosides/pharmacology , Kidney/metabolism , Macrophages/drug effects , Male , Myeloid Differentiation Factor 88/genetics , Myeloid Differentiation Factor 88/metabolism , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , RNA, Messenger/metabolism , Rats, Wistar
8.
Phytomedicine ; 20(10): 820-7, 2013 Jul 15.
Article in English | MEDLINE | ID: mdl-23664882

ABSTRACT

Breviscapine is a flavonoid extracted from a Chinese herb Erigeron breviscapus, previously it was shown that treatment with breviscapine attenuated renal injury in the diabetic rats. The purpose of this study was to investigate whether breviscapine combined with enalapril (an ACE inhibitor) have superior renoprotective effects against diabetic nephropathy. Rats were randomly separated into five groups: control, diabetes, diabetes treated with enalapril, diabetes treated with breviscapine, or diabetes treated with combined enalapril with breviscapine. Twenty-four hours urinary AER and the levels of 3-NT in renal tissue and MDA in renal tissue and urine as well as activities and expression of PKC in renal tissue were determined, and renal tissue morphology were observed by light microscopy after 8 weeks. Expression of TGFß1 protein was performed by immunohistochemistry method. Increased AER and kidney pathologic injury were attenuated by treatment with either enalapril or breviscapine and further reduced by the combination of the two. Elevated 3-NT in renal tissue and MDA levels in renal tissue and urine were reduced by enalapril or breviscapine and, more effectively, by combined enalapril with breviscapine. PKC activities and expression were higher in renal tissue in diabetic rats than those of the control group, which were reduced by both monotherapies, and further abrogated by combination therapy in both cases. Overexpression of TGFß1 protein observed in the glomeruli and tubulointerstitium of diabetic rats was attenuated by enalapril or breviscapine to a similar lever and further reduced by the combination of the two. The combination of enalapril and breviscapine confers superiority over monotherapies on renoprotection, which mechanism may be at least partly correlated with synergetic suppression on increased oxidative stress and PKC activities as well as overexpression of TGFß1 in renal tissue.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Diabetic Nephropathies/prevention & control , Enalapril/therapeutic use , Flavonoids/therapeutic use , Kidney/drug effects , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Animals , Diabetes Mellitus, Experimental/complications , Diabetic Nephropathies/etiology , Drug Therapy, Combination , Enalapril/pharmacology , Flavonoids/pharmacology , Kidney/metabolism , Kidney/pathology , Male , Phytotherapy , Random Allocation , Rats , Rats, Wistar , Transforming Growth Factor beta1/biosynthesis , Transforming Growth Factor beta1/genetics
9.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao ; 34(6): 590-4, 2012 Dec.
Article in Chinese | MEDLINE | ID: mdl-23286404

ABSTRACT

OBJECTIVE: To study the expressions and clinical significances of p-extracellular regulated kinase(P-ERK)1/2 and matrix metalloproteinase-9(MMP-9)in cervical squamous cell carcinoma. METHODS: The expressions of P-ERK1/2 and MMP-9 in 30 cases with chronic cervicitis, 45 cases with cervical intraepithelial neoplasia (CIN), and 58 cases with cervical squamous cell carcinoma were detected by immunohistochemical method. RESULTS: The positive rates of P-ERK1/2 and MMP-9 in chronic cervicitis, CIN, and cervical squamous cell carcinoma were 0 and 0, 28.9% and 24.4%, 77.6% and 65.5%, respectively, showing significant differences among these three groups (χ(2)= 54.393,p=0.003;χ(2)=40.968,p=0.005). The positive rates of P-ERK1/2 and MMP-9 in patients at clinical stages 2-3, at G3, with lymphatic metastasis, or with a tumor diameter greater than 4 cm were significantly higher than those at clinical stage 1(p=0.015,p=0.002), at G1-G2(p=0.013,p=0.017), without lymphatic metastasis (p=0.017,p=0.021), or with a tumor diameter less or equal than 4 cm in cervical squamous cell carcinoma(p=0.008,p=0.004). There was a positive correlation between P-ERK1/2 and MMP-9 in cervical squamous cell carcinoma (χ(2)=8.955,p=0.006). CONCLUSIONS: The expressions of P-ERK1/2 and MMP-9 increase gradually with the progression of cervical squamous cell carcinoma. The over expressions of P-ERK1/2 and MMP-9 may promote the infiltration of cervical squamous cell carcinoma and lymphatic metastasis, druing which these two enzymes may exert their effects in a synergistic manner.


Subject(s)
Carcinoma, Squamous Cell/enzymology , Matrix Metalloproteinase 9/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Uterine Cervical Neoplasms/enzymology , Carcinoma, Squamous Cell/pathology , Female , Humans , Mitogen-Activated Protein Kinase 1/metabolism , Uterine Cervical Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...